Search company, investor...

Predict your next investment

National Cancer Institute company logo
Government
cancer.gov

Investments

205

Portfolio Exits

28

Partners & Customers

10

About National Cancer Institute

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's National Cancer Institute is the principal agency for cancer research and training. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. It was founded in 1937 and is based in Bethesda, Maryland.

Headquarters Location

6116 Executive Boulevard Suite 300

Bethesda, Maryland, 20892,

United States

800-422-6237

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest National Cancer Institute News

Air quality and residential greenness influence childhood cancer development

Feb 22, 2024

In a new study led by the University of Minnesota's Masonic Cancer Center and the U of M Medical School, researchers found that exposure to air pollution and vegetation may impact childhood cancer development. The study was published in the Journal of the National Cancer Institute. The population-based study, led by U of M Medical School Assistant Professor Lindsay Williams, MPH, PhD, in collaboration with U of M Institute for Health Informatics Assistant Professor David Haynes, PhD, examined over 6,000 children with cancer and 109,000 children without cancer in Texas. The study found that from 1995-2011 increasing exposure to fine particulate matter (PM2.5) during the birth year increased the risk of developing any childhood cancer and specifically lymphoid leukemia, lymphoma, ependymoma, retinoblastoma and thyroid carcinoma. As a childhood cancer epidemiologist, I am always concerned with identifying factors that increase risk of cancer development in kids. There is growing evidence that air pollution during pregnancy and fetal development increases the risk of developing some diseases in children, including cancer." Dr. Lindsay Williams, MPH, PhD, Assistant Professor, U of M Medical School Williams noted that identifying particular exposures that could decrease the risk for developing childhood cancer has proven challenging in the past as there are very few of these that have been identified to date. To that end, her team decided to examine environmental exposures that might reduce the risk of developing childhood cancers. To do so, they examined the association between residential greenness -; or vegetation density around the home -; and childhood cancer risk, as plants can remove up to 20% of PM2.5 from the air. Findings indicate that increasing exposure to residential greenness reduced the risk of developing ependymoma and medulloblastoma -; the two most commonly diagnosed malignant brain tumors in children. These associations for PM2.5 and greenness also remained after accounting for both co-exposures in the team's statistical models, suggesting that these exposures independently modulate risk for some childhood cancers. Related Stories

National Cancer Institute Investments

205 Investments

National Cancer Institute has made 205 investments. Their latest investment was in Armida Labs as part of their Grant on October 02, 2023.

CBI Logo

National Cancer Institute Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/2/2023

Grant

Armida Labs

$0.4M

Yes

2

9/12/2023

Grant - VI

Icahn School of Medicine at Mount Sinai

$3.4M

Yes

2

8/10/2023

Grant - IV

CivaTech Oncology

$4M

No

1

8/8/2023

Grant - III

Subscribe to see more

$99M

Subscribe to see more

10

8/7/2023

Grant - V

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/2/2023

9/12/2023

8/10/2023

8/8/2023

8/7/2023

Round

Grant

Grant - VI

Grant - IV

Grant - III

Grant - V

Company

Armida Labs

Icahn School of Medicine at Mount Sinai

CivaTech Oncology

Subscribe to see more

Subscribe to see more

Amount

$0.4M

$3.4M

$4M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

1

10

10

National Cancer Institute Portfolio Exits

28 Portfolio Exits

National Cancer Institute has 28 portfolio exits. Their latest portfolio exit was Carmot Therapeutics on December 04, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/4/2023

Acquired

$99M

8

8/23/2023

Acquired

$99M

3

6/21/2023

Acquired

$99M

3

12/12/2022

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2022

Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/4/2023

8/23/2023

6/21/2023

12/12/2022

12/2/2022

Exit

Acquired

Acquired

Acquired

Acq - Pending

Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

8

3

3

10

10

National Cancer Institute Partners & Customers

10 Partners and customers

National Cancer Institute has 10 strategic partners and customers. National Cancer Institute recently partnered with Medidata on October 10, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

10/4/2023

Partner

United States

Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years. Continued Collaboration Supports Clinical Trials to Advance Cancer Research across Thousands of Oncology Studies.

Since the inception of their partnership in 2008 , Medidata and the National Cancer Institute have collaborated across thousands of clinical trials with the joint mission of pioneering the development of promising treatments of cancer - a leading cause of mortality in the United States .

1

10/3/2023

Partner

United States

GigaGen inks deal with National Cancer Institute to advance GIGA-564

Barcelona , Spain-based plasma-derived medicine specialist Grifols says that its biotech subsidiary GigaGen has signed an agreement with the National Cancer Institute , part of the USA 's National Institutes of Health , to advance development of the company 's differentiated anti-CTLA-4 antibody drug candidate for cancer treatment , GIGA-564 .

1

9/5/2023

Partner

, and United States

Mississippi’s Cervical Cancer Deaths Indicate Broader Health Care Problems

In partnership with the University of National Cancer Institute , she said , the University of health department is conducting a study to evaluate risk and look for new biomarkers in women undergoing screening for cervical cancer .

1

8/9/2023

Vendor

United States

Subscribe to see more

Subscribe to see more

10

7/26/2023

Vendor

United States

Subscribe to see more

Subscribe to see more

10

Date

10/4/2023

10/3/2023

9/5/2023

8/9/2023

7/26/2023

Type

Partner

Partner

Partner

Vendor

Vendor

Business Partner

Country

United States

United States

, and United States

United States

United States

News Snippet

Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years. Continued Collaboration Supports Clinical Trials to Advance Cancer Research across Thousands of Oncology Studies.

Since the inception of their partnership in 2008 , Medidata and the National Cancer Institute have collaborated across thousands of clinical trials with the joint mission of pioneering the development of promising treatments of cancer - a leading cause of mortality in the United States .

GigaGen inks deal with National Cancer Institute to advance GIGA-564

Barcelona , Spain-based plasma-derived medicine specialist Grifols says that its biotech subsidiary GigaGen has signed an agreement with the National Cancer Institute , part of the USA 's National Institutes of Health , to advance development of the company 's differentiated anti-CTLA-4 antibody drug candidate for cancer treatment , GIGA-564 .

Mississippi’s Cervical Cancer Deaths Indicate Broader Health Care Problems

In partnership with the University of National Cancer Institute , she said , the University of health department is conducting a study to evaluate risk and look for new biomarkers in women undergoing screening for cervical cancer .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

National Cancer Institute Team

2 Team Members

National Cancer Institute has 2 team members, including former Chief Information Officer, George Komatsoulis.

Name

Work History

Title

Status

George Komatsoulis

Chief Information Officer

Former

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

George Komatsoulis

Subscribe to see more

Work History

Title

Chief Information Officer

Subscribe to see more

Status

Former

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.